MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/rheumatology/keae575

Медицинская библиотека · Rheumatology (Oxford, England) · 2025

Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab.

Parodis Ioannis, Lindblom Julius, Tsoi Alexander, Palazzo Leonardo, Blomkvist Sporre Karin, Enman Yvonne, Nikolopoulos Dionysis, Beretta Lorenzo

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Upon commencement of therapy for active disease, patients with systemic lupus erythematosus (SLE) show varying evolution regarding disease activity measures and patient-reported outcomes (PROs). Our objective was to identify disease evolution trajectories to gain a deeper understanding of SLE progression, ultimately improving future trial design.

METHODS

Patients with ≥2 visits and available data on Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG), Physician Global Assessment (PGA), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and glucocorticoid use were included in a post hoc analysis of four randomized controlled trials of belimumab (BLISS-52, BLISS-76, BLISS-SC, EMBRACE). Growth mixture modelling identified latent classes.

RESULTS

Among 2868 patients analysed, baseline median disease duration was 4.5 (interquartile range: 1.5-9.7) years and mean (±standard deviation) Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI) 0.7 (±2.0), SLEDAI-2K 10.2 (±3.6), BILAG 17.0 (±7.8), PGA 1.5 (±0.5), FACIT-F 30.6 (±11.9) and prednisone dose 11.0 (±8.9) mg/day. In the initial model, glucocorticoid use and dose yielded high standard errors, indicating a weak link with the latent process. A refined model considered only clinical measures and FACIT-F, corrected for intervention and SDI; no other covariates improved the fit. Four classes best described disease evolution: highly active, responders; highly active, non-responders; moderately active, responders; moderately active, non-responders. Lupus Low Disease Activity State and Definitions of Remission in SLE remission attainment associated with latent classes.

CONCLUSION

By linking disease activity measures with PROs, we identified four distinct trajectories describing SLE evolution following the initiation of therapy. This classification could be valuable for personalizing treatment and guiding biological studies aimed at distinguishing patients with varying anticipated treatment responses, as no single clinical variable alone can predict disease progression.

Для цитирования: Parodis Ioannis, Lindblom Julius, Tsoi Alexander, Palazzo Leonardo, Blomkvist Sporre Karin, Enman Yvonne, Nikolopoulos Dionysis, Beretta Lorenzo. Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab.. Rheumatology (Oxford, England). 2025. DOI: 10.1093/rheumatology/keae575.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.